tiprankstipranks

Tryptamine Therapeutics to Launch Groundbreaking Trial for Binge Eating Disorder

Story Highlights
Tryptamine Therapeutics to Launch Groundbreaking Trial for Binge Eating Disorder

Elevate Your Investing Strategy:

Tryptamine Therapeutics ( (AU:TYP) ) has shared an announcement.

Tryptamine Therapeutics has established a framework for a world-first clinical trial to treat Binge Eating Disorder (BED) using TRP-8803, in collaboration with Swinburne University. The trial aims to assess the safety and efficacy of TRP-8803, administered with psychotherapy, in BED patients, potentially impacting the treatment landscape for this prevalent disorder in the US and Australia.

More about Tryptamine Therapeutics

Tryptamine Therapeutics Limited is a clinical-stage biopharmaceutical company focused on developing TRP-8803, a proprietary psilocin-based, IV-infused formulation with neuroplastic benefits.

Average Trading Volume: 1,474,349

Technical Sentiment Signal: Sell

Current Market Cap: A$46.05M

Find detailed analytics on TYP stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1